Browsing University Publications by Author "Mraiche, Fatima"
Now showing items 1-4 of 4
-
An Examination of the Employment Preparedness, Job Satisfaction, and Impact in the Workplace of Qatar University Pharmacy Alumni: A Mixed Methods Study
Al-Nuaimi, Mounyah Waiel; Abidi, Ranin; Mukhalalati, Banan; El-Awaisi, Alla; Awaisu, Ahmed; Diab, Mohhamed; Mraiche, Fatima... more authors ... less authors ( Qatar University Press , 2021 , Poster)Introduction: The level of alumni's job satisfaction and preparedness has been found to affect the impact in the workplace. Little is known about alumni's employment experience in Qatar. Objective: The aim of this study ... -
Examination of Job Satisfaction, Achievements, and Employment Preparedness among College of Pharmacy Alumni: A Study From Qatar
Al-Hathal, Turfa Awrans; Al-Ghazal, Lolwa; Mukhalalati, Banan; Awaisu, Ahmed; El-Awaisi, Alla; Mraiche, Fatima; Diab, Mohammad; Stewart, Derek; Elshami, Sara... more authors ... less authors ( Qatar University Press , 2021 , Poster)Background: Job satisfaction in healthcare is of special interest as has a direct relation with the quality of care provided to patients. It is affected by several factors including the nature of the work, level of educational ... -
Glucose and transferrin liganded PLGA nanoparticles internalization in non-small cell lung cancer cells
Benammar, Sarra; Mraiche, Fatima; Mariam Joseph, Jensa; Gorachinova, Katerina ( Qatar University Press , 2020 , Poster)Introduction: Recently, after a decade of confusing results, several studies pointed out that overexpression of GLUT1 (glucose transporter 1) is a biomarker of worse prognosis in NSCLC. Nonetheless, the presence of Transferrin ... -
The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target?
Al-Shamasi, Al-Anood; Elsayed, Meram; Abdulrahman, Nabeel; Joseph, Jensa; Mraiche, Fatima ( Qatar University Press , 2020 , Poster)Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attention due to a recent clinical trial, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG ...